Single inhaler triple therapy in COPD – all that glitters is not gold
The recent studies on combination triple therapy of inhaled corticosteroid, long acting beta2 agonist and long-acting muscarinic antagonist (ICS-LABA-LAMA) in COPD have consistently demonstrated an improvement in exacerbation frequency and/or improvement of lung function...
Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with Fluticasone furoate/Umeclidinium/Vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2020;201:1508-16. DOI: https://doi.org/10.1164/rccm.201911-2207OC
Casas A, Montes de Oca M, Menezes AM, et al. Respiratory medication used in COPD patients from seven latin american countries: the LASSYC study. Int J Chron Obstruct Pulmon Dis 2018;13:1545-56. DOI: https://doi.org/10.2147/COPD.S154097
Buhl R, Criée C-P, Kardos P, et al. Patients in clinical trials on COPD triple therapy compared to real world populations Am J Respir Crit Care Med 2019;199:A1117. DOI: https://doi.org/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1117
Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016;4:390-8. DOI: https://doi.org/10.1016/S2213-2600(16)00100-4
Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004;126:59-65. DOI: https://doi.org/10.1378/chest.126.1.59
Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018;6:747-8. DOI: https://doi.org/10.1016/S2213-2600(18)30327-8
Palli SR, Frazer M, DuCharme M, et al. Differences in real-world health and economic outcomes among patients with COPD treated with combination tiotropium/olodaterol versus triple therapy. J Manag Care Spec Pharm 2020;26:1363-74. DOI: https://doi.org/10.18553/jmcp.2020.20159
Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020;383:35-48. DOI: https://doi.org/10.1056/NEJMoa1916046
- Abstract views: 394
- PDF: 228
Copyright (c) 2021 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.